Whether you qualify for Zepbound (tirzepatide) comes down to three separate questions: do you meet the FDA-approved medical criteria, does your body mass index (BMI) clear the threshold for your indication, and will your insurance or chosen access route actually pay for it. These are not the same hurdle, and many people who are eligible on paper still get denied at the pharmacy counter for a coverage reason rather than a medical one. This guide breaks down exactly what Zepbound is approved for, the BMI and comorbidity requirements written into the FDA label, who should not take it, and how the obstructive sleep apnea pathway changed the eligibility picture in 2026.
🔑 Key Takeaways
- Zepbound is FDA-approved for adults with a BMI of 30 or higher (obesity), or 27 or higher (overweight) plus at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.[1][3]
- A second pathway exists: Zepbound is the first drug approved to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, approved December 20, 2024.[2]
- Zepbound is contraindicated if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or a serious hypersensitivity to tirzepatide.[1]
- Meeting the FDA criteria does not guarantee coverage. Medicare Part D cannot pay for Zepbound for weight loss alone, but it may cover the OSA indication.[8]
- It is approved for adults 18 and older only, and is not for type 1 or type 2 diabetes glucose control (that is Mounjaro, the same molecule under a different brand).[1][10]
What Is Zepbound Approved For?
Zepbound is the brand name for tirzepatide, a once-weekly subcutaneous injection that activates two gut-hormone receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. The U.S. Food and Drug Administration has cleared it for two distinct indications, and which one applies to you changes both the BMI math and what your insurer is allowed to cover.[1]
The two FDA-approved indications are:
- Chronic weight management. To reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight who also have at least one weight-related condition. This was the original approval, granted November 8, 2023.[3]
- Moderate-to-severe obstructive sleep apnea (OSA). To treat moderate-to-severe OSA in adults with obesity. This was added December 20, 2024, making Zepbound the first prescription medicine FDA-approved for sleep apnea.[2]
Both indications require the same lifestyle pairing: a reduced-calorie diet and increased physical activity. Tirzepatide is also sold as Mounjaro for type 2 diabetes, but that is a separate brand and a separate indication. Zepbound itself is not approved to control blood sugar in diabetes; if blood sugar is the goal, that conversation belongs with the Mounjaro label. For a deeper look at how the molecule actually works, see our explainer on how Zepbound works.
Zepbound BMI Requirements: Do You Qualify?
The single most important number in Zepbound eligibility is your BMI. The FDA label is explicit: for chronic weight management, you need a BMI of 30 kg/m2 or greater (the clinical definition of obesity), or a BMI of 27 kg/m2 or greater (the overweight range) combined with at least one weight-related comorbid condition.[1][4]
BMI is calculated as weight in kilograms divided by height in meters squared, and the standard adult categories used by the CDC and NIDDK are: 18.5 to 24.9 is healthy weight, 25.0 to 29.9 is overweight, and 30.0 or above is obesity.[4][5] Because most people think in pounds and feet, the table below converts those two key thresholds into actual body weights so you can check yourself in a few seconds.
BMI 27 and BMI 30 in Real Weight (by height)
| Height | Weight at BMI 27 (overweight + condition) | Weight at BMI 30 (obesity) |
|---|---|---|
| 5 ft 0 in (152 cm) | 138 lb (63 kg) | 153 lb (69 kg) |
| 5 ft 2 in (157 cm) | 147 lb (67 kg) | 164 lb (74 kg) |
| 5 ft 4 in (163 cm) | 157 lb (71 kg) | 174 lb (79 kg) |
| 5 ft 6 in (168 cm) | 167 lb (76 kg) | 186 lb (84 kg) |
| 5 ft 8 in (173 cm) | 177 lb (80 kg) | 197 lb (89 kg) |
| 5 ft 10 in (178 cm) | 188 lb (85 kg) | 209 lb (95 kg) |
| 6 ft 0 in (183 cm) | 199 lb (90 kg) | 221 lb (100 kg) |
| 6 ft 2 in (188 cm) | 210 lb (95 kg) | 233 lb (106 kg) |
Weights are rounded to the nearest pound. BMI is a screening tool, not a diagnosis; a clinician interprets it alongside your overall health. Athletes with high muscle mass can have an elevated BMI without excess body fat.[4]
The BMI 27 catch most people miss
If your BMI is between 27 and 29.9, you are eligible only if you also carry at least one weight-related condition. Without a documented comorbidity, a BMI in that band does not meet the label. This is also the most common reason a prior authorization gets bounced: the BMI clears 27, but no qualifying condition is recorded in the chart.[1]
What Counts as a Weight-Related Condition?
The FDA label and approval announcement name the most common qualifying comorbidities explicitly: high blood pressure (hypertension), type 2 diabetes, and high cholesterol (dyslipidemia).[3] In real-world prescribing, clinicians and insurers also commonly recognize the following weight-related conditions for the BMI 27 to 29.9 group:
- Hypertension (high blood pressure)
- Type 2 diabetes mellitus
- Dyslipidemia (high cholesterol or triglycerides)
- Obstructive sleep apnea
- Cardiovascular disease
- Metabolic dysfunction-associated steatotic liver disease (formerly fatty liver disease)
The exact list a given insurer will accept can vary by plan, so it is worth confirming with your prescriber that a qualifying diagnosis is documented before submission. Our guide to Zepbound insurance coverage and prior authorization walks through how plans evaluate these criteria.
The Obstructive Sleep Apnea Pathway
The December 2024 OSA approval created a second, separate door into Zepbound eligibility, and it matters more than most people realize. Under this indication, the requirement is a diagnosis of moderate-to-severe OSA in an adult with obesity, rather than the weight-loss criteria alone.[2]
The approval was based on the SURMOUNT-OSA program, two 52-week phase 3 trials in adults with moderate-to-severe OSA (an apnea-hypopnea index, or AHI, of at least 15 events per hour) and obesity (BMI of 30 or greater). The results were substantial:[6]
- Study 1 (participants not using a PAP machine): AHI fell by 25.3 events per hour with tirzepatide versus 5.3 with placebo, alongside a 17.7% reduction in body weight.[6]
- Study 2 (participants using a PAP machine): AHI fell by 29.3 events per hour with tirzepatide versus 5.5 with placebo, alongside a 19.6% reduction in body weight.[6]
The FDA noted the improvement in AHI is likely driven by the weight loss itself.[2] The practical eligibility takeaway: if you have a formal sleep-study diagnosis of moderate-to-severe OSA and obesity, you may qualify through this pathway even if a weight-management plan would not cover you, because some insurers treat OSA as a medical (non-weight-loss) indication. Note the OSA dosing is also narrower, with a maintenance dose of 10 mg or 15 mg once weekly rather than the 5 mg option available for weight management.[1]
Eligibility at a Glance: The Two Pathways
| Criterion | Chronic weight management | Obstructive sleep apnea |
|---|---|---|
| Minimum BMI | 30, or 27 with a weight-related condition | 30 (obesity), per the trial criteria |
| Additional diagnosis needed | A comorbidity only if BMI is 27 to 29.9 | Moderate-to-severe OSA on a sleep study (AHI 15+) |
| Age | Adults 18 and older | Adults 18 and older |
| Maintenance dose | 5 mg, 10 mg, or 15 mg weekly | 10 mg or 15 mg weekly |
| Lifestyle requirement | Reduced-calorie diet + activity | Reduced-calorie diet + activity |
| Medicare Part D coverage | Not allowed for weight loss alone | Possible (treated as a medical indication) |
Source: FDA prescribing information and approval announcements.[1][2][3][8]
Who Should NOT Take Zepbound (Contraindications)
Some people are excluded regardless of BMI. The Zepbound label carries a boxed warning and a short list of absolute contraindications. You should not take Zepbound if any of the following apply:[1]
- Personal or family history of medullary thyroid carcinoma (MTC). In rats, tirzepatide caused thyroid C-cell tumors; whether it does so in humans is unknown, but the contraindication stands as a precaution.[1]
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a genetic condition associated with MTC.[1]
- Known serious hypersensitivity to tirzepatide or any of the inactive ingredients in Zepbound.[1]
Beyond the absolute contraindications, the label flags several situations that call for caution or a different plan. These are not automatic disqualifiers, but they require a careful conversation with your clinician:[1]
- A history of pancreatitis or gallbladder disease.
- Severe gastrointestinal disease, including severe gastroparesis (Zepbound is not recommended here).
- Diabetic retinopathy, which should be monitored for progression.
- Use with insulin or insulin secretagogues, which can raise hypoglycemia risk.
- A history of depression or suicidal thoughts, which should be monitored.
- Pregnancy or planning pregnancy; weight loss is not recommended during pregnancy, and you should tell your clinician about any planned surgery because of an aspiration risk under anesthesia.
For the full safety picture, see our breakdown of Zepbound side effects and the broader tirzepatide side effects guide.
Do I Qualify for Zepbound? A Quick Decision Flow
Use this step-by-step screen to see where you likely land before you book an appointment. It mirrors how a prescriber works through the FDA criteria.
| Step | Question | If yes | If no |
|---|---|---|---|
| 1 | Are you 18 or older? | Continue | Not eligible (adults only) |
| 2 | Personal/family history of MTC or MEN 2? | Not eligible (contraindicated) | Continue |
| 3 | Is your BMI 30 or higher? | Likely eligible (weight pathway) | Continue to step 4 |
| 4 | Is your BMI 27 to 29.9 with a weight-related condition? | Likely eligible (weight pathway) | Continue to step 5 |
| 5 | Do you have moderate-to-severe OSA + obesity? | Possibly eligible (OSA pathway) | Likely not eligible by label |
| 6 | Does your insurance cover your indication? | Confirm prior authorization | Explore cash-pay or telehealth options |
This is an educational screen, not medical advice. Only a licensed clinician can determine whether Zepbound is appropriate for you.
Meeting the Criteria vs Getting It Covered
Here is the part that trips up the most people: clearing the FDA criteria is necessary but not sufficient. Coverage is a separate gate, and it is where many eligible patients stall.
Federal law is the clearest example. Medicare Part D is statutorily barred from covering drugs used solely for weight loss, which means even a clearly eligible Medicare beneficiary cannot get Zepbound paid for under the weight-management indication. The OSA approval is significant precisely because it is a medical indication that can sidestep that exclusion, and some Medicare plans now cover Zepbound for sleep apnea.[8] Commercial insurers vary widely: some require a documented period of supervised lifestyle change, a minimum BMI higher than the FDA floor, or step therapy through another agent first.
If insurance will not pay, eligibility is still meaningful because cash-pay and telehealth routes exist. Compare your options in our guides to GLP-1 cost without insurance and the best online GLP-1 programs, and weigh Zepbound against its closest competitor in Zepbound vs Wegovy.
If you are close but not over the line
If your BMI sits just under 27, or just under 30 with no comorbidity, you do not meet the current label. That does not mean nothing helps; lifestyle change, and in some cases other medications, may be appropriate. A clinician-led telehealth evaluation is the cleanest way to confirm your status and document any qualifying condition you may already have.
Frequently Asked Questions
The Bottom Line
Zepbound eligibility starts with two numbers and one question. A BMI of 30 or higher puts you in the obesity pathway. A BMI of 27 to 29.9 works only if a weight-related condition is on record. And a moderate-to-severe sleep apnea diagnosis with obesity opens a second door that did not exist before December 2024. Run yourself through the BMI table and the decision flow above, rule out the contraindications, and then treat coverage as a distinct project: meeting the medical criteria is step one, getting your plan or an access route to pay for it is step two.
References
- FDA. Zepbound (tirzepatide) Highlights of Prescribing Information, January 2026 label.
- FDA. FDA Approves First Medication for Obstructive Sleep Apnea (December 20, 2024).
- FDA. FDA Approves New Medication for Chronic Weight Management (November 8, 2023).
- CDC. Adult BMI Categories.
- NIDDK (NIH). Definition and Facts for Adult Overweight and Obesity.
- Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med. 2024. PMC11598664.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID 35658024.
- KFF. An Overview of Medicare (Part D coverage of obesity and anti-obesity drugs).
- SURMOUNT-1 full text and BMI inclusion criteria. PMC9486455.
- MedlinePlus (NIH). Tirzepatide Injection: drug information.
